Early Changes in Body Composition After Cessation of Growth Hormone Therapy in Childhood-Onset Growth Hormone Deficiency

Journal of Clinical Densitometry

Volumn 14, Issue 4, 2011, Pages 471-477

  Bechtold, Susanne ^a   Bachmann, Sara ^a   Putzker, Stephanie ^a   Dalla Pozza, Robert ^a   Schwarz, Hans Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Body composition; Bone density; Bone geometry; Growth hormone; Transition

Indexed keywords

ESTRADIOL; GLUCOCORTICOID; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; TESTOSTERONE; THYROID HORMONE;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; DIAPHYSIS; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL THERAPY; HUMAN; INSULIN TOLERANCE TEST; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METAPHYSIS; OLECRANON; ONSET AGE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SEXUAL DEVELOPMENT;

ADOLESCENT; BODY COMPOSITION; CHILD; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; LIPIDS; MALE; RADIUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 82855178800     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.05.001     Document Type: Article

References (32)

1. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
2. Woodhouse L.J., Mukherjee A., Shalet S.M., Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 2006, 27:287-317.
3. Cuneo R.C., Salomon F., McGauley G.A., Sönksen P.H. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992, 37:387-397.
4. Coloa A., Di Somma C., Salerno M., et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002, 87:3650-3655.
5. Gasco V., Corneli G., Beccuti G., et al. Retesting the childhood-onset GH-deficient patient. Eur J Endocrinol 2008, (159 Suppl 1):45-52.
6. Ho K.K. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007, 157:695-700.
7. Clayton P.E., Cuneo R.C., Juul A., et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005, 152:165-170.
8. Carroll P.V., Drake W.M., Maher K.T., et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004, 89:3890-3895.
9. Frost H.M. Defining osteopenias and osteoporoses: another view (with insights from a new paradigm). Bone 1997, 20:385-391.
10. Schönau E., Neu C., Beck B., et al. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. J Bone Miner Res 2002, 17:1095-1101.
11. Marin G., Domene H.M., Barnes K.M., et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994, 79:537-541.
12. Bonfig W., Bechtold S., Bachmann S., et al. Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab 2008, 21:1049-1056.
13. Brandt I., Reinken L. The growth rate of healthy children in the first 16 years: Bonn-Dortmund longitudinal developmental study. Klin Paediatr 1988, 200:451-456.
14. Tanner J. Growth at adolescence 1962, Blackwell, Oxford, UK, 28-39.
15. Neu C., Manz F., Rauch F., et al. Bone density and bone size at the distal radius in healthy children and adolescents: a study using peripheral quantitative computed tomography. Bone 2001, 28:227-232.
16. Neu C., Rauch F., Manz F., Schoenau E. Modeling of cross-sectional bone size and geometry at the proximal radius-a study of normal bone development using peripheral quantitative computed tomography. Osteoporos Int 2001, 12:538-547.
17. Elmlinger M.W., Kuhnel W., Weber M.M., Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004, 42:654-664.
18. Schoenau E., Neu C., Rauch F., Manz F. The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab 2001, 86:613-618.
19. Attanasio A.F., Howell S., Bates P.C., et al. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002, 87:3368-3372.
20. Boot A.M., van der Sluis I.M., Krenning E.P., de Muinck Keizer-Schrama S.M. Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 2009, 71:364-371.
21. Rauch F., Bailey D.A., Baxter-Jones A., et al. The 'muscle-bone unit' during the pubertal growth spurt. Bone 2004, 34:771-775.
22. Rauch F., Bailey D.A., Baxter-Jones A., et al. Bone growth in length and width: the Yin and Yang of bone stability. J Musculoskelet Neuronal Interact 2005, 5:194-201.
23. Hogler W., Shaw N. Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) 2010, 72:281-289.
24. Ohlsson C., Bengtsson B.A., Isaksson O.G., et al. Growth hormone and bone. Endocr Rev 1998, 19:55-79.
25. Mauras N., Pescovitz O.H., Allada V., et al. Transition Study Group: limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005, 90:3946-3955.
26. Fors H., Bjarnason R., Wirént L., et al. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents. Clin Endocrinol 2001, 55:617-624.
27. Murray R.D., Adams J.E., Shalet S.M. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab 2006, 91:432-438.
28. Johannsson G., Albertsson-Wikland K., Bengtsson B.A. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999, 84:4516-4524.
29. Evans L.M., Davies J.S., Anderson R.A., et al. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000, 142:254-262.
30. Mohn A., Marzio D., Giannini C., et al. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy. Clin Endocrinol (Oxf) 2005, 63:537-542.
31. Cuneo R.C., Salomon F., Watts G.F., et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993, 42:1519-1523.
32. Salomon F., Cuneo R.C., Hesp R., Sönksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321:1797-1803.